ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender ...